



Insurance Tracker

Motilal Oswal values your support in the Asiamoney Brokers Poll 2023 for India Research, Sales, Corporate Access and Trading team. We request your ballot.



Premium and YoY growth (%)

GWP, INRb	May-23	YoY
Grand Total	182	18
Total Public	62	13
Total Private	97	21
SAHI	21	23
Bajaj Allianz	10	12
ICICI -Lombard	17	21
New India	24	10
Star Health	10	16

Source: General Insurance Council, MOFSL

Strong growth in Health & Motor insurance

SAHIs outperform private multi-line players and the overall industry

- In May'23, the gross written premium (GWP) for the industry grew 18% YoY to INR182b, led by the Health (up 21% YoY) and Motor (up 23% YoY) segments. The Crop segment saw a healthy premium growth of 34.5% YoY. The Fire segment and Commercial lines relatively underperformed with a muted YoY growth of 5.9% and 9.4%, respectively.
- SAHIs/private multi-line players reported GWP of INR21b/INR96.9b in May'23, up 23%/21% YoY. On the other hand, PSU players reported a 13% YoY growth to INR62.4b, lower than the industry.
- Among key players, ICICIGI grew 21% YoY in May'23 (higher than the industry growth), whereas STARHEAL reported GWP growth of 16% YoY. Bajaj Allianz reported GWP growth of 12% YoY, whereas New India reported a YoY growth of 10%.

Health business up 21% YoY, led by higher growth in group segment

The Health business grew 21% YoY, with both Retail/Group Health segments reporting a growth of 18%/32%. In Apr'23, private players reported a 25% YoY growth in Health premiums, higher than the overall Health industry growth. The overseas Health segment also grew at a decent pace of 24% YoY. SAHIs reported a 24% YoY growth in Health GWP. Within SAHIs, STARHEAL and Aditya Birla reported a YoY growth of 16% and 3%, respectively. This is because STARHEAL reported a weaker growth (15%) than its peers in the Retail Health segment, whereas Aditya Birla reported a decline of 4% in the Group Health segment. As per our interaction with the management, STARHEAL's Retail Health growth is expected to recover in Jun'23. Manipal Cigna and CARE outperformed its peers in the Retail Health segment, whereas Niva Bupa (erstwhile Max Bupa) outperformed its peers in the Group Health business. Within the Retail Health segment, STARHEAL reported a weaker growth of 15% YoY and other SAHIs registered a YoY growth of 32%. ILOM grew 47% YoY, outperforming the industry and posted a 25%/55% YoY growth in Retail Health/Group Health in May'23. PSU multi-line players posted a growth of 9%/25% in the Retail Health and Group Health segments, respectively.

Motor segment clocks a healthy growth of 23%

The Motor business grew 23% YoY, primarily driven by the Motor OD segment (up 27% YoY). PSU players outperformed private multi-line players in the Motor OD segment, but underperformed in the Motor TP segment. ILOM underperformed peers in the Motor OD (11% YoY growth) and Motor TP (2% YoY growth) segments. Bajaj Allianz posted a healthy growth of 31% YoY with Motor OD and Motor TP registering a growth of 42%/22% YoY. Acko General posted a strong growth of 50% in Motor OD but a muted growth of 12% in Motor TP segments. Go Digit also registered a strong growth of 56%/79% in the Motor TP/ Motor OD segments.

May'23 performance of key players

SAHIs/private multi-line players gained ~65bp/~165bp market share during May'23, while public players lost ~255bp.

- ILOM reported a growth of 21% YoY (market share of 10.2% v/s 10.3%).
- Bajaj Allianz posted a growth of 12% YoY (market share of 6.0% v/s 5.9%).
- New India recorded a growth of 10% YoY (market share of 17.1% v/s 18.5%).
- STARHEAL registered a growth of 16% YoY (market share of 4.2% v/s 4.1%).

Prayesh Jain - Research Analyst (Prayesh.Jain@MotilalOswal.com)

Research Analyst: Nemin Doshi (Nemin. Doshi@MotilalOswal.com) | Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com)





Exhibit 1: Overall premium growth and market share

				GWP			Market share (%)			
INR b	May-23	May-22	YoY (%)	YTDFY24	YTDFY23	YoY (%)	YTDFY24	YTDFY23	YoY bps	
Acko General	1.6	1.0	66%	2.9	1.9	47%	0.7%	0.5%	12	
Bajaj Allianz	10.0	8.9	12%	26.4	21.7	22%	6.0%	5.9%	13	
Cholamandalam MS	5.2	3.8	37%	11.6	8.5	37%	2.6%	2.3%	33	
Edelweiss	0.4	0.3	58%	1.0	0.6	57%	0.2%	0.2%	5	
Future Generali	3.2	2.6	24%	8.4	6.1	39%	1.9%	1.7%	26	
Go Digit	5.8	4.8	19%	14.0	10.8	30%	3.2%	2.9%	27	
HDFC ERGO	10.2	8.6	18%	24.5	21.3	15%	5.6%	5.8%	-20	
Navi General *	0.1	0.1	-22%	0.1	0.2	-38%	0.0%	0.0%	-2	
ICICI -Lombard	17.3	14.3	21%	44.7	37.8	18%	10.2%	10.3%	-10	
IFFCO -Tokio	7.2	5.7	26%	17.2	12.4	39%	3.9%	3.4%	55	
Kotak Mahindra	1.1	0.7	55%	2.1	1.4	56%	0.5%	0.4%	11	
Liberty General	1.5	1.2	27%	4.0	3.3	22%	0.9%	0.9%	2	
Magma HDI	1.6	1.5	4%	3.9	3.4	14%	0.9%	0.9%	-4	
Raheja QBE	0.1	0.4	-69%	0.2	0.7	-67%	0.1%	0.2%	-14	
Reliance General	7.2	6.4	13%	18.4	16.0	15%	4.2%	4.4%	-17	
Royal Sundaram	2.2	2.1	4%	5.6	4.8	15%	1.3%	1.3%	-5	
SBI General	6.0	5.3	12%	12.2	11.3	8%	2.8%	3.1%	-30	
Shriram General	1.8	1.2	45%	3.4	2.3	45%	0.8%	0.6%	14	
Tata-AIG	11.2	8.7	29%	26.8	20.2	32%	6.1%	5.5%	60	
Universal Sompo	3.3	2.7	22%	6.8	5.3	27%	1.5%	1.5%	9	
Private Players	96.9	80.3	21%	234.4	190.1	23%	53.5%	51.8%	166	
United India	14.7	14.3	3%	32.9	30.5	8%	7.5%	8.3%	-82	
National	9.8	7.8	26%	21.6	19.5	11%	4.9%	5.3%	-38	
New India	24.2	22.1	10%	74.8	67.9	10%	17.1%	18.5%	-144	
Oriental	13.8	11.2	23%	29.1	24.2	21%	6.7%	6.6%	7	
Public Players	62.4	55.3	13%	158.4	142.1	12%	36.2%	38.7%	-257	
Aditya Birla	1.7	1.7	3%	4.3	3.5	25%	1.0%	0.9%	4	
ManipalCigna	1.1	0.8	34%	2.5	1.9	28.4%	0.6%	0.5%	4	
Max Bupa	3.7	2.6	43%	7.3	5.0	47.3%	1.7%	1.3%	32	
Care Insurance	4.4	3.4	31%	9.5	7.1	34.5%	2.2%	1.9%	24	
Star Health	10.0	8.6	16%	18.2	15.2	20.1%	4.2%	4.1%	2	
SAHI	21.0	17.1	23%	41.8	32.6	28.3%	9.5%	8.9%	66	
AIC (Crop)	0.7	0.5	60%	1.9	0.5	291.9%	0.4%	0.1%	30	
ECGC (Export & Credit)	0.9	0.8	9%	1.6	1.5	4.7%	0.4%	0.4%	-5	
Specialized PSU	1.6	1.3	27%	3.5	2.0	74.7%	0.8%	0.5%	25	
Industry	182	154	18%	438	367	19%	100.0%	100.0%	0	





Exhibit 2: Industry segmental performance and product mix

				Product Mix					
INR b	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY	YTDFY24	YTDFY23	YoY bps
Fire	21.3	20.1	5.9%	71.0	66.5	6.7%	16.2%	18.1%	-193
Marine Total	3.7	3.8	-2.5%	11.1	10.8	2.9%	2.5%	2.9%	-41
Motor Total	61.8	50.1	23.2%	121.6	98.8	23.1%	27.8%	26.9%	83
Motor OD	25.5	20.1	27.2%	50.3	40.1	25.4%	11.5%	10.9%	55
Motor TP	36.3	30.1	20.6%	71.3	58.7	21.5%	16.3%	16.0%	28
Health Total	71.2	58.7	21.1%	178.6	145.7	22.6%	40.8%	39.7%	105
Health Retail	28.1	23.9	17.6%	53.7	45.4	18.1%	12.2%	12.4%	-13
Health Group	41.4	31.2	32.4%	108.3	86.0	25.9%	24.7%	23.4%	127
Govt Schemes	0.5	2.6	-82.3%	14.4	12.5	15.7%	3.3%	3.4%	-11
Overseas	1.2	1.0	24.0%	2.2	1.8	23.8%	0.5%	0.5%	2
Crop	4.1	3.1	34.5%	6.5	3.6	79.6%	1.5%	1.0%	49
Others	19.9	18.2	9.4%	49.2	41.4	19.0%	11.2%	11.3%	-4
Total	182.0	154.0	18.1%	438.1	366.8	19.4%	100.0%	100.0%	0

Exhibit 3: Growth in Motor OD premium and market share

	Motor OD						Market share			
INR m	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY	YTDFY24	YTDFY23	YoY bps	
Acko General	179	119	50%	353	224	58%	0.7%	0.6%	14	
Bajaj Allianz	2,090	1,471	42%	4,070	2,956	38%	8.1%	7.4%	72	
Cholamandalam MS	1,578	1,045	51%	3,333	2,079	60%	6.6%	5.2%	144	
Edelweiss	122	81	51%	223.6	154	45%	0.4%	0.4%	6	
Future Generali	681	569	20%	1,470	1,151	28%	2.9%	2.9%	5	
Go Digit	1,358	759	79%	2,640	1,505	75%	5.2%	3.7%	150	
HDFC ERGO	1,346	1,148	17%	2,671	2,243	19%	5.3%	5.6%	-28	
Navi General *	1	4	-86%	0.9	10	-91%	0.0%	0.0%	-2	
ICICI -Lombard	2,991	2,685	11%	5,826	5,532	5%	11.6%	13.8%	-221	
IFFCO -Tokio	1,843	1,160	59%	3,603	2,212	63%	7.2%	5.5%	165	
Kotak Mahindra	245	165	48%	500	364	37%	1.0%	0.9%	9	
Liberty General	645	442	46%	1,269	872	46%	2.5%	2.2%	35	
Magma HDI	317	493	-36%	605	974	-38%	1.2%	2.4%	-122	
Raheja QBE	11	198	-94%	18.9	362	-95%	0.0%	0.9%	-86	
Reliance General	1,096	1,049	5%	2,134	2,189	-3%	4.2%	5.5%	-121	
Royal Sundaram	760	651	17%	1,477	1,259	17%	2.9%	3.1%	-20	
SBI General	688	811	-15%	1,333	1,761	-24%	2.6%	4.4%	-174	
Shriram General	358	226	59%	665	429	55%	1.3%	1.1%	25	
Tata-AIG	2,429	1,736	40%	4,790	3,526	36%	9.5%	8.8%	73	
Universal Sompo	655	861	-24%	1,158	1,475	-21%	2.3%	3.7%	-137	
Private Players	19,392	15,672	24%	38,140	31,276	22%	75.8%	77.9%	-215	
United India	1,282	993	29%	2,545	2,005	27%	5.1%	5.0%	6	
National	1,533	957	60%	3,048	1,915	59%	6.1%	4.8%	128	
New India	2,527	1,857	36%	5,044	3,801	33%	10.0%	9.5%	55	
Oriental	775	579	34%	1,561	1,142	37%	3.1%	2.8%	26	
Public Players	6,116	4,385	39%	12,198	8,863	38%	24.2%	22.1%	215	
Industry	25,508	20,058	27%	50,338	40,139	25%	100.0%	100.0%	0	

Source: General Council of India, MOFSL





Exhibit 4: Growth in Motor TP premium and market share

			Me	otor TP			Market share			
INR m	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY	YTDFY24	YTDFY23	YoY bps	
Acko General	317	284	12%	634	538	18%	0.9%	0.9%	-3	
Bajaj Allianz	2,279	1,861	22%	4,558	3,752	21%	6.4%	6.4%	0	
Cholamandalam MS	2,004	1,550	29%	4,125	3,015	37%	5.8%	5.1%	65	
Edelweiss	91	74	23%	161.9	136	19%	0.2%	0.2%	-1	
Future Generali	841	662	27%	1,738	1,396	25%	2.4%	2.4%	6	
Go Digit	2,446	1,565	56%	5,043	3,192	58%	7.1%	5.4%	163	
HDFC ERGO	1,592	1,398	14%	3,139	2,719	15%	4.4%	4.6%	-23	
Navi General *	3	22	-87%	5.1	45	-89%	0.0%	0.1%	-7	
ICICI -Lombard	3,017	2,957	2%	6,027	6,056	0%	8.5%	10.3%	-187	
IFFCO -Tokio	1,709	1,290	32%	3,230	2,375	36%	4.5%	4.0%	48	
Kotak Mahindra	222	147	51%	459	278	65%	0.6%	0.5%	17	
Liberty General	445	342	30%	887	682	30%	1.2%	1.2%	8	
Magma HDI	818	801	2%	1,558	1,580	-1%	2.2%	2.7%	-51	
Raheja QBE	30	71	-58%	60	133	-55%	0.1%	0.2%	-14	
Reliance General	1,506	1,234	22%	2,860	2,294	25%	4.0%	3.9%	10	
Royal Sundaram	905	737	23%	1,716	1,469	17%	2.4%	2.5%	-10	
SBI General	694	1,004	-31%	1,424	2,038	-30%	2.0%	3.5%	-148	
Shriram General	1,250	919	36%	2,318	1,692	37%	3.3%	2.9%	37	
Tata-AIG	3,301	2,048	61%	6,615	4,127	60%	9.3%	7.0%	224	
Universal Sompo	759	712	7%	1,351	1,180	14%	1.9%	2.0%	-12	
Private Players	24,228	19,676	23%	47,908	38,699	24%	67.2%	66.0%	124	
United India	3,247	2,807	16%	6,219	5,341	16%	8.7%	9.1%	-38	
National	2,770	2,097	32%	5,347	4,023	33%	7.5%	6.9%	64	
New India	4,137	3,816	8%	8,121	7,378	10%	11.4%	12.6%	-119	
Oriental	1,877	1,678	12%	3,685	3,216	15%	5.2%	5.5%	-31	
Public Players	12,031	10,398	16%	23,371	19,957	17%	32.8%	34.0%	-124	
Industry	36,260	30,074	21%	71,279	58,655	22%	100.0%	100.0%	0	





Exhibit 5: Growth in Motor premium and market share

	Motor Total			Market share			
INR m	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY bps	
Acko General	495	403	23%	0.8%	0.8%	4	
Bajaj Allianz	4,370	3,332	31%	7.1%	6.8%	30	
Cholamandalam MS	3,583	2,595	38%	6.1%	5.2%	98	
Edelweiss	213	155	37%	0.3%	0.3%	2	
Future Generali	1,522	1,232	24%	2.6%	2.6%	6	
Go Digit	3,804	2,324	64%	6.3%	4.8%	156	
HDFC ERGO	2,938	2,546	15%	4.8%	5.0%	-25	
Navi General *	4	27	-86%	0.0%	0.1%	-5	
ICICI -Lombard	6,008	5,641	6%	9.7%	11.7%	-198	
IFFCO -Tokio	3,552	2,450	45%	5.6%	4.6%	97	
Kotak Mahindra	467	312	50%	0.8%	0.7%	14	
Liberty General	1,089	783	39%	1.8%	1.6%	20	
Magma HDI	1,136	1,294	-12%	1.8%	2.6%	-81	
Raheja QBE	41	269	-85%	0.1%	0.5%	-44	
Reliance General	2,602	2,283	14%	4.1%	4.5%	-43	
Royal Sundaram	1,665	1,388	20%	2.6%	2.8%	-14	
SBI General	1,381	1,814	-24%	2.3%	3.8%	-158	
Shriram General	1,608	1,145	40%	2.5%	2.1%	31	
Tata-AlG	5,729	3,784	51%	9.4%	7.7%	163	
Universal Sompo	1,413	1,573	-10%	2.1%	2.7%	-62	
Private Players	43,620	35,348	23%	70.8%	70.8%	-7	
United India	4,529	3,800	19%	7.2%	7.4%	-23	
National	4,303	3,054	41%	6.9%	6.0%	89	
New India	6,664	5,673	17%	10.8%	11.3%	-49	
Oriental	2,652	2,257	18%	4.3%	4.4%	-10	
Public Players	18,148	14,784	23%	29.2%	29.2%	7	
Industry	61,768	50,132	23%	100.0%	100.0%	0	





Exhibit 6: Growth in Health premium and market share

	Overall Health						Market share			
INR m	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY	YTDFY24	YTDFY23	YoY bps	
Acko General	941	474	98%	1,585	1,026	54%	0.9%	0.7%	18	
Bajaj Allianz	2,095	2,831	-26%	6,289	5,793	9%	3.5%	4.0%	-46	
Cholamandalam MS	560	373	50%	1,310	928	41%	0.7%	0.6%	10	
Edelweiss	99	31	224%	341.6	188	82%	0.2%	0.1%	6	
Future Generali	747	402	86%	2,033	914	122%	1.1%	0.6%	51	
Go Digit	981	484	103%	3,246	1,355	139%	1.8%	0.9%	89	
HDFC ERGO	3,862	3,340	16%	8,464	7,224	17%	4.7%	5.0%	-22	
Navi General*	52	41	26%	94	89	5%	0.1%	0.1%	-1	
ICICI -Lombard	5,990	4,080	47%	14,309	10,002	43%	8.0%	6.9%	115	
IFFCO -Tokio	1,267	1,373	-8%	4,692	2,892	62%	2.6%	2.0%	64	
Kotak Mahindra	430	255	68%	808	444	82%	0.5%	0.3%	15	
Liberty General	235	199	18%	1,025	987	4%	0.6%	0.7%	-10	
Magma HDI	280	110	155%	891	295	202%	0.5%	0.2%	30	
Raheja QBE	16	7	115%	19.3	25	-22%	0.0%	0.0%	-1	
Reliance General	1,392	1,084	28%	4,699	3,366	40%	2.6%	2.3%	32	
Royal Sundaram	353	460	-23%	884	915	-3%	0.5%	0.6%	-13	
SBI General	2,031	1,499	35%	3,884	2,625	48%	2.2%	1.8%	37	
Shriram General	3	2	73%	6	1	329%	0.0%	0.0%	0	
Tata-AIG	2,087	1,740	20%	4,369	3,376	29%	2.4%	2.3%	13	
Universal Sompo	247	115	114%	1,027	666	54%	0.6%	0.5%	12	
Private Players	23,665	18,900	25%	59,976	43,113	39%	33.6%	29.6%	399	
United India	5,792	6,236	-7%	16,159	14,669	10%	9.0%	10.1%	-102	
National	3,010	2,735	10%	7,541	8,257	-9%	4.2%	5.7%	-145	
New India	10,462	8,635	21%	40,004	36,423	10%	22.4%	25.0%	-260	
Oriental	7,771	5,765	35%	14,234	11,835	20%	8.0%	8.1%	-15	
Public Players	27,035	23,370	16%	77,937	71,184	9%	43.6%	48.9%	-523	
Aditya Birla	1,609	1,559	3%	4,005	3,257	23%	2.2%	2.2%	1	
ManipalCigna	1,070	800	34%	2,413	1,887	28%	1.4%	1.3%	6	
Max Bupa	3,672	2,556	44%	7,170	4,850	48%	4.0%	3.3%	68	
Care Insurance	4,267	3,096	38%	9,164	6,457	42%	5.1%	4.4%	70	
Star Health	9,840	8,466	16%	17,967	14,952	20%	10.1%	10.3%	-20	
SAHI	20,458	16,478	24%	40,719	31,404	30%	22.8%	21.6%	124	
Industry	71,157	58,748	21%	1,78,632	1,45,700	23%	100.0%	100.0%	0	





Exhibit 7: Growth in Retail Health premium and market share

	-		Retail	Health			Market share		
INR m	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY	YTDFY24	YTDFY23	YoY bps
Acko General	19	2	1187%	37	3	1312%	0.1%	0.0%	6
Bajaj Allianz	693	594	17%	1,304	1,149	14%	2.4%	2.5%	-10
Cholamandalam MS	421	316	33%	922	632	46%	1.7%	1.4%	33
Edelweiss	7	9	-27%	22.8	14	68%	0.0%	0.0%	1
Future Generali	145	115	26%	285	229	25%	0.5%	0.5%	3
Go Digit	41	33	26%	79	59	34%	0.1%	0.1%	2
HDFC ERGO	2,578	2,330	11%	4,918	4,351	13%	9.2%	9.6%	-41
Navi General*	40	26	52%	77.1	51	50%	0.1%	0.1%	3
ICICI -Lombard	881	704	25%	1,671	1,346	24%	3.1%	3.0%	15
IFFCO -Tokio	170	149	14%	314	264	19%	0.6%	0.6%	0
Kotak Mahindra	71	70	2%	113	109	3%	0.2%	0.2%	-3
Liberty General	51	42	20%	105	78	35%	0.2%	0.2%	2
Magma HDI	29	26	9%	56	48	17%	0.1%	0.1%	0
Raheja QBE	3	2	89%	4.6	3	48%	0.0%	0.0%	0
Reliance General	257	172	50%	518	345	50%	1.0%	0.8%	21
Royal Sundaram	164	155	5%	312	301	3%	0.6%	0.7%	-8
SBI General	438	368	19%	767	641	20%	1.4%	1.4%	2
Shriram General	3	2	73%	6	1	329%	0.0%	0.0%	1
Tata-AIG	569	467	22%	1,074	849	26%	2.0%	1.9%	13
Universal Sompo	78	80	-2%	156	170	-8%	0.3%	0.4%	-8
Private Players	6,658	5,661	18%	12,742	10,643	20%	23.7%	23.4%	31
United India	1,178	957	23%	2,222	2,003	11%	4.1%	4.4%	-27
National	1,651	1,627	1%	3,323	3,337	0%	6.2%	7.3%	-115
New India	1,947	1,826	7%	4,179	3,908	7%	7.8%	8.6%	-82
Oriental	1,364	1,224	11%	2,774	2,537	9%	5.2%	5.6%	-42
Public Players	6,139	5,634	9%	12,498	11,785	6%	23.3%	25.9%	-266
Aditya Birla	672	586	15%	1,280	1,102	16%	2.4%	2.4%	-4
ManipalCigna	504	365	38%	964	696	39%	1.8%	1.5%	26
Max Bupa	2,607	2,062	26%	4,815	3,874	24%	9.0%	8.5%	44
Care Insurance	2,420	1,683	44%	4,785	3,407	40%	8.9%	7.5%	142
Star Health	9,091	7,901	15%	16,583	13,919	19%	30.9%	30.6%	26
SAHI	15,293	12,596	21%	28,427	22,998	24%	53.0%	50.6%	234
Industry	28,090	23,891	18%	53,666	45,425	18%	100.0%	100.0%	0





Exhibit 8: Growth in Group Health premium and market share

			Retai	Health			N	/larket share	•
INR m	May-23	May-22	YoY	YTDFY24	YTDFY23	YoY	YTDFY24	YTDFY23	YoY bps
Acko General	19	2	1187%	37	3	1312%	0.1%	0.0%	6
Bajaj Allianz	693	594	17%	1,304	1,149	14%	2.4%	2.5%	-10
Cholamandalam MS	421	316	33%	922	632	46%	1.7%	1.4%	33
Edelweiss	7	9	-27%	22.8	14	68%	0.0%	0.0%	1
Future Generali	145	115	26%	285	229	25%	0.5%	0.5%	3
Go Digit	41	33	26%	79	59	34%	0.1%	0.1%	2
HDFC ERGO	2,578	2,330	11%	4,918	4,351	13%	9.2%	9.6%	-41
Navi General*	40	26	52%	77.1	51	50%	0.1%	0.1%	3
ICICI -Lombard	881	704	25%	1,671	1,346	24%	3.1%	3.0%	15
IFFCO -Tokio	170	149	14%	314	264	19%	0.6%	0.6%	0
Kotak Mahindra	71	70	2%	113	109	3%	0.2%	0.2%	-3
Liberty General	51	42	20%	105	78	35%	0.2%	0.2%	2
Magma HDI	29	26	9%	56	48	17%	0.1%	0.1%	0
Raheja QBE	3	2	89%	4.6	3	48%	0.0%	0.0%	0
Reliance General	257	172	50%	518	345	50%	1.0%	0.8%	21
Royal Sundaram	164	155	5%	312	301	3%	0.6%	0.7%	-8
SBI General	438	368	19%	767	641	20%	1.4%	1.4%	2
Shriram General	3	2	73%	6	1	329%	0.0%	0.0%	1
Tata-AIG	569	467	22%	1,074	849	26%	2.0%	1.9%	13
Universal Sompo	78	80	-2%	156	170	-8%	0.3%	0.4%	-8
Private Players	6,658	5,661	18%	12,742	10,643	20%	23.7%	23.4%	31
United India	1,178	957	23%	2,222	2,003	11%	4.1%	4.4%	-27
National	1,651	1,627	1%	3,323	3,337	0%	6.2%	7.3%	-115
New India	1,947	1,826	7%	4,179	3,908	7%	7.8%	8.6%	-82
Oriental	1,364	1,224	11%	2,774	2,537	9%	5.2%	5.6%	-42
Public Players	6,139	5,634	9%	12,498	11,785	6%	23.3%	25.9%	-266
Aditya Birla	672	586	15%	1,280	1,102	16%	2.4%	2.4%	-4
ManipalCigna	504	365	38%	964	696	39%	1.8%	1.5%	26
Max Bupa	2,607	2,062	26%	4,815	3,874	24%	9.0%	8.5%	44
Care Insurance	2,420	1,683	44%	4,785	3,407	40%	8.9%	7.5%	142
Star Health	9,091	7,901	15%	16,583	13,919	19%	30.9%	30.6%	26
SAHI	15,293	12,596	21%	28,427	22,998	24%	53.0%	50.6%	234
Industry	28,090	23,891	18%	53,666	45,425	18%	100.0%	100.0%	0

Investment in securities market are subject to market risks. Read all the related documents carefully before investing





Explanation of Investment Rating	Explanation of Investment Rating						
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	< - 10%						
NEUTRAL	> - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (RSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onl

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

- In the past 12 months, MOFSL or any of its associates may have:
 a) received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report, b)
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, C)
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock

No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com_Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Kule 15a-6(b)(4) of the Exchange Act

16 June 2023 9





and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore,

as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates from a connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates from any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Offevalue Neuressal Cell.									
Contact Person	Contact No.	Email ID							
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com							
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com							
Mr. Ajay Menon	022 40548083	am@motilaloswal.com							

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

16 June 2023